![Governor John Carney, Lieutenant Governor Bethany Hall-Long, Mayor Kenneth Branner Jr, Delaware Prosperity Partnership President Kurt Foreman, WuXi AppTec Chairman and CEO Dr Ge Li, WuXi AppTec Co-CEO and WuXi STA CEO Dr Minzhang Chen, and others celebrating the groundbreaking for the WuXi STA Middletown campus [Credit: WuXi STA].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/WuXi-STA-groundbreaking-scaled-e1660730270899-300x278.jpeg)
![Governor John Carney, Lieutenant Governor Bethany Hall-Long, Mayor Kenneth Branner Jr, Delaware Prosperity Partnership President Kurt Foreman, WuXi AppTec Chairman and CEO Dr Ge Li, WuXi AppTec Co-CEO and WuXi STA CEO Dr Minzhang Chen, and others celebrating the groundbreaking for the WuXi STA Middletown campus [Credit: WuXi STA].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/WuXi-STA-groundbreaking-scaled-e1660730270899.jpeg)
news
WuXi STA breaks ground on new Delaware manufacturing facility
The new 190-acre pharmaceutical manufacturing campus will provide formulation development, clinical and commercial drug product manufacturing services.
List view / Grid view
Contract Manufacturing
news
Queen’s Award for Enterprise goes to SGS’s Quay Pharma
SGS’s CDMO Quay Pharma awarded UK’s highest accolade for business success in overseas sales, Queen's Award for Enterprise: International Trade.
news
Samsung Biologics recognised for sustainable growth
The Frost & Sullivan Institute to present CDMO Samsung Biologics with a Global Enlightened Growth Leadership Award for its commitment to sustainable growth and protecting and prolonging human lives.
news
Lonza to build €500m fill and finish facility in Stein
The large-scale commercial drug product fill and finish facility will be built at Lonza’s existing site in Stein, Switzerland, with completion expected in 2026.
news
Lonza and Kodiak open custom-built bioconjugation facility
The newly opened facility will support the rapid launch and commercial manufacturing of KSI-301, Kodiak’s investigational retinal disease therapeutic.
news
Collaboration between Lonza and IBF to progress Israeli biologics sector
Israel Biotech Fund (IBF) and Lonza announce agreement to accelerate the development and manufacture of Israeli biologics and small molecules.
news
Emergent destroyed almost 400mn COVID-19 vaccines due to quality issues, finds report
US Government investigation report suggests Emergent Biosolutions destroyed almost 400 million doses of COVID-19 vaccine and worked to conceal quality issues from the FDA.
![PCI Pharma Services logo on sign outside Canadian facility [Credit: JHVEPhoto/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/PCI-Pharma-Services-300x278.jpg)
![PCI Pharma Services logo on sign outside Canadian facility [Credit: JHVEPhoto/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/PCI-Pharma-Services-e1653043421551.jpg)
news
PCI Pharma Services announces major manufacturing expansion with $100 Million investment in New England, providing global capacity to clients
Capabilities include the latest in sterile lyophilisation and liquid filling technology to support global pharmaceutical supply chain, keeping pace with industry trends.
news
WuXi Biologics awarded for excellence
WuXi Biologics awarded the Bioprocessing Excellence in Viral Clearance and Safety accolade for the second time at the Asia-Pacific Bioprocessing Excellence Awards (ABEA) 2022 event.
news
Expanding API manufacturing operations: Cambrex and Asymchem
Cambrex expands API manufacturing capacity at flagship US facility and Asymchem completes construction of two new Chinese API production sites.
![Recipharm logo on building in Bordeaux, France[Credit: sylv1rob1/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Recipharm-300x278.jpg)
![Recipharm logo on building in Bordeaux, France[Credit: sylv1rob1/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Recipharm.jpg)
news
Recipharm builds biologics presence with acquisitions
The closing of two biologics acquisitions will help Recipharm establish itself in the advanced therapy medicinal products space.
news
Catalent acquires new biologics facility in the UK
Catalent announces the expansion of its biologics development and manufacturing capability by purchasing a new facility, currently under construction in Oxford, UK.
news
FUJIFILM acquires new cell therapy manufacturing facility
FUJIFILM Diosynth Biotechnologies will run the cell therapy manufacturing facility, acquired for $100mn from Atara Biotherapeutics, as part of its global network.
![WuXi Biologics logo on a lit up phone screen [Credit: Piotr Swat/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/WuXi-Biologics-300x278.jpg)
![WuXi Biologics logo on a lit up phone screen [Credit: Piotr Swat/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/WuXi-Biologics.jpg)
news
WuXi announces record figures after successful year
Global biotechnology company WuXi has demonstrated the success of the CRDMO business model by publishing news of its bumper projects and revenues fuelled by innovative technology platforms in 2021.
news
Intravacc publishes GMP vaccine candidate manufacturing process
A new paper details the GMP manufacturing and formulation process for a semi-synthetic Shigella glycoconjugate vaccine candidate from Institut Pasteur.
